You are here

Rigosertib

Onconova reports PhIII flop, putting high-risk MDS program on the chopping block

Endpoints

Mon, 08/24/20 - 10:32 am

clinical trials

myelodysplastic syndrome

More job cuts at Onconova

Bizjournals.com

Wed, 08/31/16 - 08:47 pm

Baxter spinoff cancels potential $565M partnership with Bucks County biotech firm

Bizjournals.com

Sat, 03/5/16 - 09:51 am

Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls

Yahoo/Zacks.com

Wed, 02/26/14 - 10:50 am

Isis Pharmaceuticals

Vertex Pharmaceuticals

Onconova hammered after top drug rigosertib flunks key PhIII study

Fierce Biotech

Thu, 02/20/14 - 05:33 pm

myelodysplastic syndromes

Onconova tanks as its lead candidate flunks PhIII for pancreatic cancer

Fierce Biotech

Wed, 12/18/13 - 12:09 pm

pancreatic cancer

Onconova says data reinforce safety/tolerability profiles of rigosertib

Yahoo/Fly on the Wall

Mon, 12/9/13 - 09:59 am

Making The Call: Onconova MDS Drug Study Will Succeed

TheStreet.com

Wed, 09/25/13 - 09:21 am

Our BioPharma Catalyst Watch List

Seeking Alpha

Thu, 08/15/13 - 12:09 pm